Nyxoah SA (NYXH)

NASDAQ · Instruments & Medical Devices · Surgical & Medical Instruments & Apparatus

Price
$1.27
Day
-4.51%

Close 2026-09-24.

The company

Overview We are a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea, or OSA. Our lead solution is the Genio system, a CE-Marked and FDA approved, patient-centric next generation hypoglossal neurostimulation, or HGNS, therapy for the treatment of moderate to severe OSA, implanted via a single-incision procedure. OSA is the world’s most common sleep disordered breathing condition and is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke. Our technology platform is a first-of-its-kind HGNS device designed to treat OSA through bilateral stimulation, by maintaining upper airway patency to reduce obstructive breathing events during sleep. We started generating revenue from the sale of the Genio system in Europe in July 2020. On August 8, 2025, the FDA approved the Genio system for a subset of adult patients with moderate to severe OSA with an Apnea-Hypopnea Index, or AHI, of greater than or equal to 15 and less than or equal to 65, and we started generating revenue from the sale of the Genio system in the U.S. in September 2025. We are building a growing body of clinical evidence to further support the strong value proposition of the Genio system and its ability to improve the health and quality of life of OSA patients. OSA occurs due to the relaxation of the soft tissue, throat and tongue muscles in a patient’s airway, which causes an obstruction that temporarily prevents breathing during sleep.

From Item 1: Overview.

Institutional holders

Largest positions reported on Form 13F for the quarter ended 2026-06-30, by value.

Recent filings